ANNOVIS BIO (ANVS)
US03615A1088 - Common Stock
Taking everything into account, ANVS scores 2 out of 10 in our fundamental rating. ANVS was compared to 568 industry peers in the Biotechnology industry. While ANVS seems to be doing ok healthwise, there are quite some concerns on its profitability. ANVS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ANVS has reported negative net income.
ANVS had a negative operating cash flow in the past year.
ANVS had negative earnings in each of the past 5 years.
In the past 5 years ANVS always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ANVS (-285.06%) is worse than 94.16% of its industry peers.
With a Return On Equity value of -579.57%, ANVS is not doing good in the industry: 80.71% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -285.06% | ||
| ROE | -579.57% | ||
| ROIC | N/A |
ROA(3y)-217.47%
ROA(5y)-161.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ANVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ANVS has more shares outstanding
The number of shares outstanding for ANVS has been increased compared to 5 years ago.
There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ANVS has an Altman-Z score of -13.82. This is a bad value and indicates that ANVS is not financially healthy and even has some risk of bankruptcy.
ANVS's Altman-Z score of -13.82 is on the low side compared to the rest of the industry. ANVS is outperformed by 80.00% of its industry peers.
ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.82 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ANVS has a Current Ratio of 2.66. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
ANVS has a worse Current ratio (2.66) than 69.20% of its industry peers.
ANVS has a Quick Ratio of 2.66. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
ANVS has a Quick ratio of 2.66. This is in the lower half of the industry: ANVS underperforms 67.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.66 | ||
| Quick Ratio | 2.66 |
3. Growth
3.1 Past
ANVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.99%, which is quite good.
EPS 1Y (TTM)14.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 15.08% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.97%
EPS Next 2Y30.22%
EPS Next 3Y20.82%
EPS Next 5Y15.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ANVS. In the last year negative earnings were reported.
Also next year ANVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ANVS's earnings are expected to grow with 20.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.22%
EPS Next 3Y20.82%
5. Dividend
5.1 Amount
ANVS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ANNOVIS BIO
NYSE:ANVS (12/20/2024, 8:04:00 PM)
After market: 4.37 0 (0%)4.37
-0.03 (-0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.65%
Inst Owner Change18.48%
Ins Owners19.65%
Ins Owner Change0%
Market Cap60.31M
Analysts81.67
Price Target35.5 (712.36%)
Short Float %11.95%
Short Ratio4.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.32%
Min EPS beat(2)-80.79%
Max EPS beat(2)50.15%
EPS beat(4)2
Avg EPS beat(4)-2.82%
Min EPS beat(4)-80.79%
Max EPS beat(4)87.72%
EPS beat(8)4
Avg EPS beat(8)-29.3%
EPS beat(12)5
Avg EPS beat(12)-41.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.58%
PT rev (3m)7.41%
EPS NQ rev (1m)-10.7%
EPS NQ rev (3m)-10.7%
EPS NY rev (1m)-21.96%
EPS NY rev (3m)-21.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.54 | ||
| P/tB | 8.54 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.63
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -285.06% | ||
| ROE | -579.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-217.47%
ROA(5y)-161.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.66 | ||
| Quick Ratio | 2.66 | ||
| Altman-Z | -13.82 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.49%
EPS Next Y69.97%
EPS Next 2Y30.22%
EPS Next 3Y20.82%
EPS Next 5Y15.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.72%
EBIT Next 3Y-11.05%
EBIT Next 5Y-29.35%
FCF growth 1Y-48.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.52%
OCF growth 3YN/A
OCF growth 5YN/A